NCT00295828

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Hermann Eye Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if a drug called Macugen may help to stop the growth of abnormal blood vessels on the iris that has occurred in the eye(s) as part of diabetic retinopathy.

Detailed description

Diabetic retinopathy is an eye condition caused by diabetes in which new blood vessels grow on the retina (the back, inside part of the eye) and the iris. These vessels are not normal and may leak or break, causing bleeding in the eye. This process can lead to vision loss or blindness, glaucoma (disease of the eye where eye pressures are usually too high resulting in damage to the optic nerve), or other eye problems. This study is to determine if a drug called Macugen may help to stop the growth of these abnormal blood vessels on the iris.

Conditions

• Iris Neovascularization
• Diabetic Retinopathy

Interventions

Type	Name	Description
OTHER	Pegaptanib Sodium Injection/Panretinal Photocoagulation	Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
PROCEDURE	Panretinal Photocoagulation (PRP)	Ocular Laser Procedure

Timeline

• Start date: 2006-01-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2006-02-24
• Last updated: 2008-09-04

Locations

1 site across 1 country: United States